Company Profile
Immunome Stock Price, News & Analysis
Company overview
Business overview
Immunome is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Immunome is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates.
Business Model Characteristics
Immunome is a pipeline-led immunology story, so the market tends to track readouts, regulatory milestones, and how the company expands from one immune program to the next.
Position Within the Biotechnology Landscape
Compared with more mature peers, Immunome sits close to the development side of the biotech landscape, where immunology data can change sentiment quickly.
Why the stock is moving
IMNM is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Immunome’s catalysts are its antibody-discovery platform and oncology pipeline, especially any update that shows the company can still produce differentiated assets. The next readout matters because the platform still needs to prove itself.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.